Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




AI Model Accurately Shows Presence and Location of Cancer in Pathological Images

By LabMedica International staff writers
Posted on 15 Aug 2022

It is usually necessary to accurately mark the location of the cancer site in pathological images to solve the problems involved with zoning that indicates the location information of cancer, which takes a long time and therefore increased cost. More...

Existing deep learning models need to construct a dataset, in which the location of the cancer was accurately drawn, to specify the cancer site. Now, researchers have developed a weakly supervised deep learning model that can accurately show the presence and location of cancer in pathological images based only on data where the cancer is present. The deep learning model improves efficiency and is expected to make a significant contribution to the relevant research field.

Scientists at Daegu Gyeongbuk Institute of Science and Technology (DGIST, Daegu, Korea) developed the weakly supervised learning model that zones cancer sites with only rough data such as 'whether the cancer in the image is present or not' is under active study. However, there would be a significant deterioration in performance if the existing weakly supervised learning model is applied to a huge pathological image dataset where the size of one image is as large as a few gigabytes. To solve this problem, the researchers attempted to improve performance by dividing the pathological image into patches, although the divided patches lose the correlation between the location information and each split data, which means that there is a limit to using all of the available information.

In response, the research team discovered a technique of segmenting down to the cancer site solely based on the learned data indicating the presence of cancer by slide. The team developed a pathological image compression technology that first teaches the network to effectively extract significant features from the patches through unsupervised contrastive learning and uses this to detect the main features while maintaining each location information to reduce the size of the image while maintaining the correlation between the patches. Later, the team developed a model that can find the regions that are highly likely to have cancer from the compressed pathology images by using a class activation map and zone all of these regions from the entire pathology images using a pixel correlation module (PCM). The newly developed deep learning model showed a dice similarity coefficient (DSC) score of up to 81-84 only with the learning data with slide-level cancer labels in the cancer zoning problem. It significantly exceeded the performance of previously proposed patch level methods or other weakly supervised learning techniques (DSC score: 20 - 70).

“The model developed through this study has greatly improved the performance of weakly supervised learning of pathological images, and it is expected to contribute to improving the efficiency of various studies requiring pathological image analysis,” said Professor Park Sang-Hyun of the Department of Robotics and Mechatronics Engineering at DGIST. “If we can improve the related technology further in the future, it will be possible to use it universally for various medical image zoning issues.”

Related Links:
DGIST 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
All-in-One Molecular System
AIO M160
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: iStock

AMP 2026 Underscores Molecular Testing’s Role in Precision Medicine for Women’s Health

Advances in molecular diagnostics are creating new opportunities to improve the detection of sexually transmitted infections, identify antibiotic resistance, and assess cancer recurrence risk in women.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.